Skip to content

Almax Pharma

Active
Private limited companyfounded 201412 yrs activeRue Saint Pierre et Paul(Thy) 10, 5651 Walcourt, BelgiumKBO/BCE: BE 0556.705.368
Summary

Almax Pharma has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €303,429 and a net result of €2,070. Equity is growing by ~8.2% per year across the filed fiscal years. Its solvency ranks better than 92% of 20110 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.8% (low).

Risk analysisWatch ReportCompare
Almax PharmaActiveChecked score 67/100
Risk analysis ReportCompare

Overview

What they do
Retail sale of pharmaceutical products
NACE 47730
1 site
How big
€346,656total assets 2025
Equity
€303,429
Profit
€2,070
Financially healthy?
67 Healthy Checked score 2025
Bankruptcy chance 12 m
0.8%
Who decides
Accounts filed 4 d late0 of 2 deeds read
Why 67- Higher-failure-rate sector- Higher-failure-rate region+ Annual accounts: healthy financial profile+ Long track recordFiled after the deadlineShow the evidence

Checked score

Score 2025
67 / 100
Healthy
Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability39▼-36
Solvency100=
Growth52=
Track record100
Bankruptcy probability, 12 months
0.8% Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €20,000 at 30 days acceptable
Liquidity ample (current ratio 8.02 against 5.83 in 2024; short-term debt: 12.5% and cash: 0.4% of total assets), and 12.5% of the assets are financed with debt.
Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Retail trade (NACE 47)
about 45% more bankruptcies
← fewer bankruptcies more bankruptcies →
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
87.5%
Return on assets
0.6%
Age of the figures
18 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation date
Age against the risk zone
highest failure risk from 2 to 8 years 12 years 0 20 y
neutral · Filed after the deadline
The financial year that closed on 31-03-2025 was due by 31-10-2025 and was filed on 04-11-2025, 4 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filings
Deviation from the deadline
2025
4 d late
2024
53 d late
2023
10 d late
2022
17 d late
2021
72 d early
2020
60 d early
2019
18 d late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 4 days before the deadline; the sector median for financial year 2024 is on the deadline day, and 47% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-03-2026 and is due by 31-10-2026. Nothing is late today. Usually files around 10 November (4 of the last 5 filed years within 43 days of that day).
Companies Code · seven months
Position in the running window
31-03-2026 close02-10-2026 today31-10-2026 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · micro…
  2. Weakest financial yearnet €2,070 ▼88.2%
  3. Annual accounts filedfiscal year 2024 · full…

Key points

  • Positive: Among the best 8% on solvencysector median 34.1% · 20,110 companies 87.5% View
  • Positive: 7 profitable years in a rowprofit 2025: €2,070 7 years View
  • Total assets 20256 fiscal years filed €346,656 View

By topic

Financials

Fiscal year
2025
Total assets
€346,656
Profit
€2,070
Solvency
87.5%
Total assets▼ 4.5%
Net result
20192025
Go to Financials

Timeline

Events
12
Since
2017
Next accounts
by 31-10-2026
  1. 04-11-2025Annual accounts filed
  2. 31-03-2025Weakest financial year
  3. 23-12-2024Annual accounts filed
Go to Timeline

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
17-07-2014
Year ends
31-03
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure